Skip to main content

Table 1 Patient characteristics

From: Prediction of the aggressiveness of non-functional pancreatic neuroendocrine tumors based on the dual-tracer PET/CT

No. patients31
Gender, Male, n (%)20 (65)
Age years, mean (SD)59.6 (17.6)
BMI, mean (SD)26.3 (4.0)
Asymptomatic, n (%)29 (90)
MEN1 syndrome, n (%)7 (23)
CgA, n (%) 
 Strongly positive3 (10)
 Weakly positive15 (48)
 Negative13 (42)
PP (pmol/L), median (IQR)68 (41–129)
5-HIAA (nmol/L), median (IQR)64 (53–64)
Primary tumor size (mm) 
 All patients, median (IQR)24 (14–35)
 Operated, median (IQR) (n = 20)31 (20–52)
 Biopsy and follow-up, median (min–max) (n = 2)24 (22–25)
 Follow-up*, median (IQR) (n = 9)14 (13–21)
Tumor localization, n (%) 
 Head12 (39)
 Body2 (6)
 Tail10 (32)
 Multiple7 (23)
Treatment, n (%) 
 Surgery20 (65)
 Biopsy and follow-up2 (6)
 Follow-up*9 (29)
Type of surgery, n (%) 
 Total pancreatectomy2 (10)
 Pancreaticoduodenectomy4 (20)
 Distal pancreatectomy13 (65)
 Enucleation1 (5)
Type of surgery, n (%) 
 Open13 (75)
 Laparoscopic5 (25)
 Robotic surgery2 (10)
Grade, n (%) 
 G113 (59)
 G28 (36)
 G3 NET1 (5)
 G3 NEC0
  1. Abbreviations: CgA, circulating chromogranin A, strongly positive indicates S-CgA = 13.5 nmol/L or P-CgA 9–37 nmol/L, weakly positive indicates S-CgA 2.2–4.7 nmol/L or P-CgA 3.0–4.8 nmol/L and negative indicates S-CgA < 2.1 nmol/L or P-CgA < 3.0 nmol/L; BMI, body mass index, kg/m2; MEN1, multiple endocrine neoplasia type 1 syndrome; PP, pancreatic polypeptide; 5-HIAA, 5-hydroxyindoleatic acid
  2. *Two patients underwent non-diagnostic EUS-FNB (endoscopic ultrasonography and fine needle biopsy)